Over-The-Counter Oral Contraceptive
On July 13, 2023, the U.S. Food and Drug Administration (FDA) approved the nonprescription sale of Opill (norgestrel) tablet, a progestin-only oral contraceptive. This groundbreaking decision marks the first instance of a daily oral contraceptive being made available over the counter in the United States, allowing individuals to purchase this pregnancy prevention method at pharmacies, grocery stores, and online. Opill's effectiveness, when used correctly, surpasses existing nonprescription methods, highlighting its potential to reduce unintended pregnancies and associated health risks. Opill's official launch is anticipated for 2024, with details regarding its availability and pricing to be determined by the manufacturer. SMFM will continue to work with the Free the Pill coalition and other partners to advocate for access to this and all other contraceptive methods.
FDA Opill information - Safety information for patients and providers
Free the Pill factsheet provides an overview of over-the-counter insurance coverage by state
Free the Pill OTC OCP research summary - Includes links to publications for further reading
ACOG Committee Opinion: Over-the-counter access to hormonal contraception
US Medical Eligibility Criteria for Contraceptive Use: Progestin-Only Contraceptives
US Selected Practice Recommendations for Contraceptive Use: Progestin-Only Pills
For Patients: ACOG FAQs Progestin-only hormonal birth control pill
For more information about SMFM’s work to improve access to contraceptive care, contact the SMFM Reproductive Health Project at RHProject@smfm.org.